EHU072401
MISSION® esiRNA
targeting human EHF
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.51
UNSPSC Code:
41105324
description
Powered by Eupheria Biotech
Quality Level
product line
MISSION®
form
lyophilized powder
esiRNA cDNA target sequence
AGCATCCATATGGCTTCGTCAAGGGAGGTGAACATTGTTGCTGAGTTAAATTCCAGGGTCTCAGATGGTTAGGACAAAGTGGATGGATGCCGGGAAGTTTAACCTGAGCCTTAGGATCCAATGAGTGGAGAATGGGGACTTCCAAAACCCAAGGTTGGCTATAATCTCTGCATAACCACATGACTTGGAATGCTTAAATCAGCAAGAAGAATAATGGTGGGGTCTTTATACTCATTCAGGAATGGTTTATCTGATGCCAGGGCTGTCTTCCTTTCTCCCCTTTGGATGGTTGGTGAAATACTTTAATTGCCCTGTCTGCTCACTTCTAGCTATTTAAGAGAGAACCCAGCTTGGTTCTTTTTTGCTCCAAGTGCTTAAAAATAAGTTGGAAAAAGGAGACGGTGGTGTG
Ensembl | human accession no.
NCBI accession no.
shipped in
ambient
storage temp.
−20°C
Gene Information
human ... EHF(26298)
General description
MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.
Legal Information
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Meng-Li Gu et al.
World journal of gastroenterology, 26(47), 7497-7512 (2021-01-02)
Gastric cancer (GC) is one of the most common and deadliest types of cancer worldwide due to its delayed diagnosis and high metastatic frequency, but its exact pathogenesis has not been fully elucidated. ETS homologous factor (EHF) is an important
Zhi Long et al.
Cell death & disease, 12(1), 46-46 (2021-01-09)
The rising of a highly aggressive subtype of castration-resistant prostate cancer (CRPC) named treatment-induced neuroendocrine prostate cancer (t-NEPC) after androgen deprivation therapy (ADT) is well known for its features of the neuroendocrine differentiation (NED) and androgen receptor (AR) independence. However
Global Trade Item Number
| SKU | GTIN |
|---|---|
| EHU072401-20UG | 04061828611805 |
| EHU072401-50UG | 04061828372287 |